Summary & Headlines:

We're back with updates in the digital health world! Read about more highlights here:

‍

Digital Therapeutics

Withings acquires Biosency and enters respiratory remote monitoring

Withings has acquired Biosency, a Rennes-based company that develops remote monitoring technology for patients with respiratory insufficiency, including a certified algorithm for early detection of COPD exacerbations. The deal is intended to expand Withings' remote monitoring capabilities and support its broader strategy of building an independent European connected health company.

FDA Clears First Over-The-Counter Continuous Glucose Monitor for Children

The FDA has cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children aged two and older who do not use insulin, marking the first such clearance for a pediatric continuous glucose monitor. The wearable sensor pairs with a smartphone app to track glucose levels every 15 minutes for up to 15 days. The device is not intended for those with problematic hypoglycemia or on dialysis, and the FDA advises caregiver supervision along with consultation with a healthcare provider before making medication adjustments based on its readings.

‍

Healthcare / IT Solutions

Microsoft and Mayo Clinic Partner on Healthcare AI Model

Microsoft and Mayo Clinic partnered to develop a healthcare-specific frontier AI model combining Mayo Clinic's de-identified longitudinal clinical data with Microsoft's AI and cloud capabilities. The model will initially be deployed and refined within Mayo Clinic to support clinical reasoning, earlier diagnosis, and personalized treatment decisions. Mayo Clinic will own the model, which Microsoft ultimately plans to make available through Azure Foundry APIs.

Abridge and NVIDIA Develop Clinical Conversation AI Model

Abridge partners with NVIDIA to develop an AI foundation model purpose-built for clinical conversations, leveraging NVIDIA's Blackwell architecture and Nemotron model family. Alongside the partnership, Abridge announced its expansion beyond clinical documentation into a broader clinician intelligence platform supporting workflows before, during, and after patient visits. The company is also extending its ambient AI capabilities to nursing workflows and positioning its platform to facilitate interactions between health systems, payers, and life sciences organizations.

Aidoc Receives FDA Breakthrough Device Designation for AI Radiology Reporting Tool

Aidoc received FDA Breakthrough Device Designation for First Read, an investigational AI tool designed to analyze chest radiographs and generate preliminary radiology report text. Built on Aidoc's CARE foundation model, the tool aims to reduce reporting bottlenecks and help radiologists manage growing imaging volumes while preserving clinician review and final approval. The designation marks Aidoc's second Breakthrough Device Designation in under a year and extends its clinical AI platform further into generative reporting workflows.

Elation Health Acquires Aster to Expand AI-Enabled EHR Capabilities

Elation Health acquired women's health EHR startup Aster, adding voice AI-driven front-office automation capabilities to its EHR and practice management platform. Aster's Atlas AI agent is designed to automate administrative tasks for independent practices, and the company's founding and technical team will join Elation. The acquisition follows Elation's recent integration of Anthropic's Claude into its EHR and reflects the company's broader push to embed AI across clinical and administrative workflows.

‍

‍

‍

Women’s Health / Femtech

Ovum raises $4M for its AI-powered women’s health platform

Australian startup Ovum raised A$4 million, tripling its reported valuation to A$18 million. Its platform allows women to consolidate and interpret health information, generate personalized insights, and better prepare for clinical conversations. Since launching in August 2025, Ovum reportedly supported more than 113,000 AI health conversations and is beginning clinical trials evaluating AI in preventive women’s healthcare. Funding will support international expansion, regulatory approvals, and further AI development. Ovum is positioning itself less as a narrow symptom tracker and more as an AI-enabled health-navigation layer. The emphasis on regulatory approval and clinical trials may help differentiate it from consumer wellness apps, while its partnerships with Medibank and other organizations suggest a potential employer, payer, and enterprise distribution model.

Clair Health raises $11.6M for a hormone-tracking wearable

Clair Health raised $11.6 million, led by Khosla Ventures, to develop a noninvasive wearable and companion app focused specifically on women’s hormonal health. The platform aims to infer cycle phase, irregularities, perimenopausal changes, inflammation, bloating, and energy patterns from continuous biometric data. It represents a shift from adding cycle-tracking features to general-purpose wearables toward building an entire wearable platform around women’s endocrinology. The combination of specialized hardware, algorithms, and longitudinal data could create opportunities across fertility, menopause, and broader hormone-related care.

‍

‍

‍

Longevity / Healthy Aging

Midjourney unveils full-body ultrasonic scanner

Midjourney, the AI image-generation company, announced a pivot into preventative health with Midjourney Medical, an ultrasonic full-body scanner designed to deliver MRI-quality imaging in roughly 60 seconds. The device uses hundreds of thousands of underwater ultrasonic sensors to map body composition and tissue down to a fraction of a millimeter. The company plans to house the scanners inside “Midjourney Spa” locations, enabling a comfortable experience for patients to gather data on their health.  

Gero raises $17M, reaching $34M in equity funding to turn the physics of aging into medicines

Gero, a Singapore- and San Francisco-based biotech, announced $17M in new financing, bringing its total equity funding to $34M, to advance AI-driven drug discovery for aging and chronic diseases. The company applies physics-first AI and human longitudinal data to develop medicines that slow aging and treat age-related diseases. Gero trained AI world models of human health on approximately 10 million longitudinal medical records to identify targets shared across multiple chronic diseases, positioning the company to push both disease-modifying and aging-slowing programs through preclinical development.

‍

‍